IMP3 and head and neck cancer: However, OS was significantly longer in patients with advanced head and neck cancer treated with LY6K, CDCA1, and IMP3 peptides who were A24(+) compared with those who were A24(–); median survival time was 4.9 versus 3.5 months; p < 0.05) [30].